ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc (HEPA)

1.41
-0.60
(-29.85%)
Closed April 22 4:00PM
1.37
-0.04
( -2.84% )
Pre Market: 8:15AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.37
Bid
1.28
Ask
1.41
Volume
2,183
0.00 Day's Range 0.00
1.22 52 Week Range 20.66
Market Cap
Previous Close
1.41
Open
-
Last Trade
13
@
1.41
Last Trade Time
08:23:58
Financial Volume
-
VWAP
-
Average Volume (3m)
81,733
Shares Outstanding
4,337,682
Dividend Yield
-
PE Ratio
-0.13
Earnings Per Share (EPS)
-10.45
Revenue
-
Net Profit
-45.34M

About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and... Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Hepion Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HEPA. The last closing price for Hepion Pharmaceuticals was $1.41. Over the last year, Hepion Pharmaceuticals shares have traded in a share price range of $ 1.22 to $ 20.66.

Hepion Pharmaceuticals currently has 4,337,682 shares outstanding. The market capitalization of Hepion Pharmaceuticals is $6.12 million. Hepion Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.13.

HEPA Latest News

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic...

Hepion Pharmaceuticals to Present at NASH-TAG 2024

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.77-35.98130841122.142.241.221059941.65685216CS
4-0.91-39.91228070182.282.89991.22542242.04456123CS
12-0.47-25.54347826091.843.48991.22817332.2049274CS
26-3.04-68.93424036284.415.29991.22735162.67096949CS
52-13.03-90.486111111114.420.661.2214904212.7112094CS
156-32.63-95.97058823533446.3681.2253245626.88295841CS
260-60.83-97.797427652762.21671.22104456045.91822697CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CYNCYNGN Inc
$ 0.2305
(90.50%)
64.22M
PEGYPineapple Energy Inc
$ 0.0658
(43.67%)
65.86M
HWHHWH International Inc
$ 1.75
(36.72%)
9.73M
NKGNNKGen Biotech Inc
$ 1.92
(30.61%)
3.16M
SMFLSmart for Life Inc
$ 5.64
(29.66%)
964.6k
ABEOAbeona Therapeutics Inc
$ 3.92
(-46.74%)
150.62k
GWAVGreenwave Technology Solutions Inc
$ 0.0689
(-45.45%)
5.09M
AUIDauthID Inc
$ 6.18
(-19.64%)
3.21k
HUGEFSD Pharma Inc
$ 0.4001
(-18.18%)
1
OCXOncocyte Corporation
$ 2.10
(-16.33%)
310
PEGYPineapple Energy Inc
$ 0.0658
(43.67%)
65.86M
CYNCYNGN Inc
$ 0.2305
(90.50%)
64.22M
HWHHWH International Inc
$ 1.75
(36.72%)
9.73M
AGBAAGBA Group Holding Ltd
$ 2.88
(15.20%)
5.67M
JAGXJaguar Health Inc
$ 0.1643
(-8.67%)
5.52M

HEPA Discussion

View Posts
Awl416 Awl416 1 day ago
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
👍️0
Monksdream Monksdream 3 months ago
HEPA new 52 week low
👍️0
Monksdream Monksdream 3 months ago
HEPA new 52 week low
👍️0
Ruffieruff Ruffieruff 9 months ago
POS
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 11 months ago
Any thoughts on whether they could see accelerated approval now? results were good and there are no good alternatives.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 11 months ago
What if it is a lush partnership instead?
👍️0
shurtha2000 shurtha2000 11 months ago
Thanks
👍️0
Disquisition Disquisition 11 months ago
Absolutely correct, sir
👍️0
make it happen make it happen 11 months ago
Don't forget it's a delinquent stock has failed to meet requirements ie r/s to raise more funds rinse and repeat for at least another 3 years and if one bad thing happens expect a 90% haircut immediately imho
👍️0
Disquisition Disquisition 11 months ago
people DUMPING knowing the OFFERING is imminent…
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 11 months ago
GOOD CALL: after R/S This could be a moon shot on good top line results
👍️0
da_stock_analyst da_stock_analyst 11 months ago
#HEPA ?? 117% move today! Looking strong and ready for tomorrow! $HEPA
👍️0
make it happen make it happen 11 months ago
R/S, huge double digit negative returns, burning capital, zero Profitability

Management Effectiveness
Return on Assets -42.63%
Return on Equity  -78.41%

Cash Flow Statement
Operating Cash Flow -33.05M
Levered Free Cash Flow -16.86M

Profitability
Profit Margin. 0.00%
Operating Margin 0.00%

Yahoo

It is losing/spending more than its market cap. Imho will fade back to singles and dilute. It can't keep operations running without selling shares to share holders.
👍️0
Disquisition Disquisition 11 months ago
Yes (for up to $350 million)

and Yes (check the latest 10Q - very little cash left on hand)
👍️0
TheFinalCD TheFinalCD 11 months ago
DO THEY HAVE A SHELF OFFERING TO DRAW FROM?

ARE THEY CURRENTLY IN NEED OF CASH FROM AN OFFERING?

Message in reply to:
Offering tonight or tomorrow. Called it
👍️0
TheFinalCD TheFinalCD 11 months ago
GOOD CALL
after R/S This could be a moon shot on good top line results
👍️ 1
Pt3 Pt3 11 months ago
Call wrong baby ....Biden say No more offering.... inflation is extremely now
👍️0
Disquisition Disquisition 11 months ago
Offering tonight or tomorrow. Called it
👍️0
Triple nickle Triple nickle 11 months ago
Might jus do it
👍️0
Triple nickle Triple nickle 11 months ago
Gotta bust thru 16.40 and hold it
👍️0
makinezmoney makinezmoney 11 months ago
$HEPA : Meeting those PRIMARY ENDPOINTS


Another MDGL kinda booster about to happen here.... now $15



GO $HEPA
👍️0
Ruffieruff Ruffieruff 11 months ago
This is not even .80c PS. Whose selling?
👍️0
shurtha2000 shurtha2000 11 months ago
$15.73 building a new base
👍️0
Disquisition Disquisition 11 months ago
DUMPED all my 7zzzz at 16
👍️0
shurtha2000 shurtha2000 11 months ago
Achieves primary and secondary endpoints its all good

https://finance.yahoo.com/news/hepion-pharmaceuticals-phase-2-altitude-110000500.html
👍️0
shurtha2000 shurtha2000 11 months ago
Will Pre-market trading be suspended ?
👍️0
tw0122 tw0122 11 months ago
830 am
Monday’s conference call update
👍️0
shurtha2000 shurtha2000 11 months ago
after R/S This could be a moon shot on good top line results
👍️ 1
Ruffieruff Ruffieruff 11 months ago
But it all. Taking knife. We are scammed.
👍️ 1
makinezmoney makinezmoney 11 months ago
$HEPA: So the RS happened........ now $9

But on a downdip........... will have to get some more if this dips sub $9


GO $HEPA
👍️0
Ruffieruff Ruffieruff 11 months ago
Your shares look like crap like the rest of us!! Pumper
👍️ 1
Ruffieruff Ruffieruff 11 months ago
Scumbags!!
👍️ 1
blue finch blue finch 12 months ago
I'd consider getting back at .36
👍️0
blue finch blue finch 12 months ago
Why
👍️0
Ruffieruff Ruffieruff 12 months ago
Good thing you dumped this dog.
👍️0
Ruffieruff Ruffieruff 12 months ago
Pumper come back. Where have you been? We need another boost and lecture. Pumper rah rah rah.
👍️0
Ruffieruff Ruffieruff 1 year ago
This is dogchit!!
👍️0
Ruffieruff Ruffieruff 1 year ago
Just added some SAB members. Lets see if we finally get some real info.
👍️0
blue finch blue finch 1 year ago
Maybe they need a new CEO
👍️0
Ruffieruff Ruffieruff 1 year ago
End of day no volume dump. Manipulation
👍️0
Ruffieruff Ruffieruff 1 year ago
How your.80’s doing. All you do is jump on momo plays and then disappear into the wind. HEPA doing it’s thing alright. Going down.
👍️ 1
CreampieMafia CreampieMafia 1 year ago
He never made it back from hawaii LOL
👍️0
blue finch blue finch 1 year ago
Big O/S here

Your thoughts on that little issue
Not very far along in the process and a very big O/S ?
👍️0
Bertsllc Bertsllc 1 year ago
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announces that its Chief Executive Officer, Robert Foster, PharmD, PhD, and its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, will be presenting during a webinar entitled “How Artificial Intelligence is Changing Drug Discovery” on Thursday, March 23rd at 1:00 p.m. Eastern Time.
https://finance.yahoo.com/news/hepion-pharmaceuticals-participate-acs-jps-201000894.html
👍️0
Ruffieruff Ruffieruff 1 year ago
Where you been. We could use you around here.
👍️0
Ruffieruff Ruffieruff 1 year ago
If possible can you post the news out this afternoon. Thx
👍️0
Ruffieruff Ruffieruff 1 year ago
Nothing but a 40k share dump a few moments ago. Also fun to be a shareholder here.
👍️0
blue finch blue finch 1 year ago
Any word on the reverse split ?
👍️0
Ruffieruff Ruffieruff 1 year ago
Still adding? It’s been real quiet since you’ve taken off elsewhere.
👍️0
blue finch blue finch 1 year ago
Any idea when the reverse split is happening ?
👍️0

Your Recent History

Delayed Upgrade Clock